Search Results - "Morris, Luc G."

Safety Recommendations for Evaluation and Surgery of the Head and Neck During the COVID-19 Pandemic by Givi, Babak, Schiff, Bradley A, Chinn, Steven B, Clayburgh, Daniel, Iyer, N Gopalakrishna, Jalisi, Scharukh, Moore, Michael G, Nathan, Cherie-Ann, Orloff, Lisa A, O'Neill, James P, Parker, Noah, Zender, Chad, Morris, Luc G T, Davies, Louise

“…The rapidly expanding novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has challenged the medical…”
Get more information

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy by Chowell, Diego, Krishna, Chirag, Pierini, Federica, Makarov, Vladimir, Rizvi, Naiyer A., Kuo, Fengshen, Morris, Luc G. T., Riaz, Nadeem, Lenz, Tobias L., Chan, Timothy A.

“…Functional diversity of the highly polymorphic human leukocyte antigen class I ( HLA -I) genes underlies successful immunologic control of both infectious…”
Get full text

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy by Chowell, Diego, Morris, Luc G T, Grigg, Claud M, Weber, Jeffrey K, Samstein, Robert M, Makarov, Vladimir, Kuo, Fengshen, Kendall, Sviatoslav M, Requena, David, Riaz, Nadeem, Greenbaum, Benjamin, Carroll, James, Garon, Edward, Hyman, David M, Zehir, Ahmet, Solit, David, Berger, Michael, Zhou, Ruhong, Rizvi, Naiyer A, Chan, Timothy A

“…CD8 T cell-dependent killing of cancer cells requires efficient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules. However,…”
Get full text

Changing Trends in the Incidence of Thyroid Cancer in the United States by Morris, Luc G T, Tuttle, R Michael, Davies, Louise

Get more information

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype by Turcan, Sevin, Rohle, Daniel, Goenka, Anuj, Walsh, Logan A., Fang, Fang, Yilmaz, Emrullah, Campos, Carl, Fabius, Armida W. M., Lu, Chao, Ward, Patrick S., Thompson, Craig B., Kaufman, Andrew, Guryanova, Olga, Levine, Ross, Heguy, Adriana, Viale, Agnes, Morris, Luc G. T., Huse, Jason T., Mellinghoff, Ingo K., Chan, Timothy A.

“…Mutation of isocitrate dehydrogenase 1 (IDH1) is shown to induce DNA hypermethylation and to remodel the epigenome to resemble that of gliomas with the CpG…”
Get full text

Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance by Tuttle, R Michael, Fagin, James A, Minkowitz, Gerald, Wong, Richard J, Roman, Benjamin, Patel, Snehal, Untch, Brian, Ganly, Ian, Shaha, Ashok R, Shah, Jatin P, Pace, Mark, Li, Duan, Bach, Ariadne, Lin, Oscar, Whiting, Adrian, Ghossein, Ronald, Landa, Inigo, Sabra, Mona, Boucai, Laura, Fish, Stephanie, Morris, Luc G T

“…Active surveillance of low-risk papillary thyroid cancer (PTC) is now an accepted alternative to immediate surgery, but experience with this approach outside…”
Get more information

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types by Chowell, Diego, Yoo, Seong-Keun, Valero, Cristina, Pastore, Alessandro, Krishna, Chirag, Lee, Mark, Hoen, Douglas, Shi, Hongyu, Kelly, Daniel W., Patel, Neal, Makarov, Vladimir, Ma, Xiaoxiao, Vuong, Lynda, Sabio, Erich Y., Weiss, Kate, Kuo, Fengshen, Lenz, Tobias L., Samstein, Robert M., Riaz, Nadeem, Adusumilli, Prasad S., Balachandran, Vinod P., Plitas, George, Ari Hakimi, A., Abdel-Wahab, Omar, Shoushtari, Alexander N., Postow, Michael A., Motzer, Robert J., Ladanyi, Marc, Zehir, Ahmet, Berger, Michael F., Gönen, Mithat, Morris, Luc G. T., Weinhold, Nils, Chan, Timothy A.

“…Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB) treatment, but current decision-making procedures have limited accuracy. In…”
Get full text

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase by Valero, Cristina, Lee, Mark, Hoen, Douglas, Zehir, Ahmet, Berger, Michael F, Seshan, Venkatraman E, Chan, Timothy A, Morris, Luc G T

“…In June 2020, the US Food and Drug Administration approved the anti-programmed cell death 1 drug pembrolizumab for patients with malignant solid tumors of any…”
Get more information

Therapeutic targeting of tumor suppressor genes by Morris, Luc G. T., Chan, Timothy A.

“…Carcinogenesis is a multistep process attributable to both gain‐of‐function mutations in oncogenes and loss‐of‐function mutations in tumor suppressor genes…”
Get full text

Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016 by Powers, Ann E, Marcadis, Andrea R, Lee, Mark, Morris, Luc G. T, Marti, Jennifer L

“…This study uses Surveillance, Epidemiology, and End Results (SEER) registry data to describe trends in thyroid cancer incidence overall and by tumor size in…”
Get full text

Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy by Ganly, Ian, Ricarte Filho, Julio, Eng, Stephanie, Ghossein, Ronald, Morris, Luc G. T, Liang, Yupu, Socci, Nicholas, Kannan, Kasthuri, Mo, Qianxing, Fagin, James A, Chan, Timothy A

“…Context: Hurthle cell cancer (HCC) is an understudied cancer with poor prognosis. Objective: Our objective was to elucidate the genomic foundations of HCC…”
Get full text

Molecular Profiling of Thyroid Nodules-Are These Findings Meaningful, or Merely Measurable?: A Review by Morris, Luc G T

“…Advances in genomic technologies have facilitated the development of sophisticated molecular diagnostic tests for thyroid nodules, in the hopes of better risk…”
Get more information

Second Primary Cancers After an Index Head and Neck Cancer: Subsite-Specific Trends in the Era of Human Papillomavirus–Associated Oropharyngeal Cancer by MORRIS, Luc G. T, SIKORA, Andrew G, PATEL, Snehal G, HAYES, Richard B, GANLY, Ian

“…Patients with head and neck squamous cell carcinoma (HNSCC) are at elevated risk of second primary malignancies (SPM), most commonly of the head and neck (HN),…”
Get full text

Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy by Iyer, N. Gopalakrishna, Morris, Luc G. T., Tuttle, R. Michael, Shaha, Ashok R., Ganly, Ian

“…BACKGROUND: American Thyroid Association guidelines currently recommend the selective use of radioactive iodine (RAI) therapy in patients with well…”
Get full text

Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base by Cracchiolo, Jennifer R., Baxi, Shrujal S., Morris, Luc G., Ganly, Ian, Patel, Snehal G., Cohen, Marc A., Roman, Benjamin R.

“…BACKGROUND There has been increasing interest in the primary surgical treatment of patients with early T classification (T1‐T2) oropharyngeal squamous cell…”
Get full text

Predictors of Survival in Mucosal Melanoma of the Head and Neck by Jethanamest, Daniel, Vila, Peter M., Sikora, Andrew G., Morris, Luc G. T.

“…Background The head and neck is the most common site of mucosal melanoma, a cancer with poor prognosis. In contrast to cutaneous melanoma, mucosal melanoma of…”
Get full text

Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis by Morris, Luc G.T., M.D, Myssiorek, David, M.D

“…Abstract Background The increasing incidence of thyroid cancer may be an artifact of increased diagnostic scrutiny, permitting detection of smaller,…”
Get full text

Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer by Morris, Luc G.T.

“…Objectives/Hypothesis Cancer cells evade recognition by the immune system to survive. Head and neck squamous cell carcinoma (HNSCC) is characterized by high…”
Get full text

Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules by Marti, Jennifer L., Avadhani, Vaidehi, Donatelli, Luke A., Niyogi, Sayani, Wang, Beverly, Wong, Richard J., Shaha, Ashok R., Ghossein, Ronald A., Lin, Oscar, Morris, Luc G. T., Ho, Allen S.

“…Background The Afirma gene expression classifier (GEC) is used to assess malignancy risk in indeterminate thyroid nodules (ITNs) classified as Bethesda…”
Get full text

Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS by Agrawal, Nishant, Jiao, Yuchen, Sausen, Mark, Leary, Rebecca, Bettegowda, Chetan, Roberts, Nicholas J, Bhan, Sheetal, Ho, Allen S, Khan, Zubair, Bishop, Justin, Westra, William H, Wood, Laura D, Hruban, Ralph H, Tufano, Ralph P, Robinson, Bruce, Dralle, Henning, Toledo, Sergio P. A, Toledo, Rodrigo A, Morris, Luc G. T, Ghossein, Ronald A, Fagin, James A, Chan, Timothy A, Velculescu, Victor E, Vogelstein, Bert, Kinzler, Kenneth W, Papadopoulos, Nickolas, Nelkin, Barry D, Ball, Douglas W

“…Context: Medullary thyroid cancer (MTC) is a rare thyroid cancer that can occur sporadically or as part of a hereditary syndrome. Objective: To explore the…”
Get full text